Aarron Willingham

Company: Merck & Co

Job title: Executive Director

Seminars:

Building TLR7 Targeted Immune Agonists 11:30 am

Examine the scientific rationale behind targeted immune agonists (TIA) targeting TLR7 Assess the design of TIA conjugates and characterization of in vitro and in vivo functional activity Develop preclinical tools to de-risk TIAs potential for induction of immune-related adverse effectsRead more

day: Conference Day 2